Orthofix Reports Strong Q4 & Full-Year 2025 Results, Guides for Continued Growth and Positive Free Cash Flow in 2026

summarizeSummary

Orthofix Medical Inc. reported strong Q4 and full-year 2025 financial results, including significant EBITDA growth and positive free cash flow, and provided optimistic 2026 guidance and long-term targets.

check_boxKey Events

• Strong Q4 2025 Financial Performance

  Reported net sales of $219.9 million (up 2% YoY) and non-GAAP pro forma net sales of $218.6 million (up 3.1% constant currency YoY). The company significantly reduced its reported net loss to $(2.2) million from $(29.1) million in Q4 2024, and non-GAAP pro forma adjusted EBITDA increased to $29.2 million (13.4% margin) from $23.9 million (11.1% margin).

• Positive Full-Year 2025 Results and Free Cash Flow

  Full-year 2025 reported net sales reached $822.3 million (up 2.9% YoY). The company achieved positive full-year 2025 free cash flow of $3.1 million (excluding M6-related restructuring charges), a significant improvement from a negative free cash flow of $(9.1) million in 2024. Non-GAAP pro forma adjusted EBITDA for the full year was $85.9 million (10.6% margin), up from $67.4 million (8.4% margin) in 2024.

• Optimistic 2026 Financial Guidance

  Orthofix expects full-year 2026 net sales to range between $850 million and $860 million, representing implied year-over-year pro forma constant currency growth of approximately 5.5% at the midpoint. Non-GAAP adjusted EBITDA is projected to be $95 million to $98 million, indicating a 70 basis points margin expansion at the midpoint, with positive free cash flow expected for the full year.

• Updated Three-Year Financial Targets (2026-2028)

  The company updated its long-term targets, affirming expectations for a 6.5% to 7.5% net sales CAGR, mid-teens non-GAAP adjusted EBITDA as a percentage of net sales by full-year 2028, and sustained positive free cash flow generation from 2026 through 2028.

auto_awesomeAnalysis

Orthofix Medical Inc. delivered a strong fourth quarter and full-year 2025, marked by significant operational improvements and a positive outlook for 2026. The company achieved its eighth consecutive quarter of adjusted EBITDA growth and generated robust free cash flow, moving to positive free cash flow for the full year 2025. This financial turnaround, coupled with solid sales growth across key segments like Bone Growth Therapies and U.S. Limb Reconstruction, indicates effective execution of its strategic initiatives. The optimistic 2026 guidance and updated three-year financial targets suggest management's confidence in sustaining above-market growth and expanding profitability, which could positively impact investor sentiment.